A growing number of studies have confirmed that TIDE scores and T cell dysfunction scores can be used to assess immunotherapy response, and higher tumor TIDE prediction scores are associated not only with poorer efficacy of immune checkpoint suppression therapy, but also with poorer patient survival under anti-PD1 and anti-CTLA4 therapy. This evidence concerns the gene PDCD1 and neoplasm.